Axicabtagene ciloleucel
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- February 2019
Comments
RED:
- Treatment of adults with relapsed or refractory follicular lymphoma after ≥3 lines of systemic therapy. (NHSE commissioned). (Decision date - October 2022)
- NICE TA872 - for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (Decision date - March 2023)
- NICE TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy. (Decision date - July 2023)
DNP:
- NICE TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma. (Decision date - July 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again